Bard C R INC Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/13/2017)
| Balance Sheet | Total Assets | 5,306,100,000.00 | ROE | – |
| Balance Sheet | Total Equity | 1,675,100,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -101,200,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 445,400,000.00 | – | – |
| Cashflow | Operating Cash Flow | 546,600,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 7.03 | Div. Yield | – |
| Income | Net Income | 531,400,000.00 | P/E | – |
| Income | Shares Outstanding | 75,200,000.00 | P/B | – |
| Income | Total Revenue | 3,714,000,000.00 | P/S | – |
Ratios calculated on: –
Company Description
C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Company participates in the markets for vascular, urology, oncology and surgical specialty products. Bard also has a product group of other products. Through subsidiaries and a joint venture, Bard markets its products to customers in over 100 countries outside the United States. The Company's principal international markets were in Europe and Japan as of December 31, 2011. On November 10, 2011, Bard acquired Medivance, Inc. On December 16, 2011, the Company acquired Lutonix, Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.crbard.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more